AgingResearch.NewsJoin free
Frontiers in Stroke

Cardiometabolic drugs after stroke: time to embrace SGLT2 inhibitors and incretin-based therapies?

By Håkon Ihle-Hansen, Hege Ihle-Hansen, Rolf Ankerlund Blauenfeldt, Show 2 more authorsGuri Hagberg
Figure 1. Approximate prevalence ranges of three common comorbidities in acute stroke: type 2 diabetes mellitus, heart failure and chronic kidney disease.
Open the figure at full size
Figure 1. Approximate prevalence ranges of three common comorbidities in acute stroke: type 2 diabetes mellitus, heart failure and chronic kidney disease.Approximate prevalence ranges of three common comorbidities in acute stroke: type 2 diabetes mellitus, heart failure and chronic kidney disease.Ihle-Hansen et al.
CommentaryInterventions
Paper

The paper

Håkon Ihle-Hansen, Hege Ihle-Hansen, Rolf Ankerlund Blauenfeldt, Show 2 more authorsGuri Hagberg

Oslo University Hospital

Frontiers in Stroke, 25 Aug 2026

doi.org/10.3389/fstro.2026.1918465PubMed 42712498

More on GLP-1 receptor agonists